Artelo's Q2 Loss, Going Concern Warning, and ATM Sales Update
ARTL is trading near its 52-week low of $0.705 (4.9% above the low) on light trading volume (0.1× avg).
Summary
Artelo Biosciences posted a $2.4 million Q2 net loss and reiterated going concern doubts. With $4.2 million in cash, the company continues to raise capital through its ATM, selling 386,668 shares after quarter-end for $354,000.
Key Events · Earnings and Guidance · ARTL
-
Q2 Net Loss of $2.4M
The second quarter of 2026 brought a net loss of $2.4 million, an improvement from the $3.2 million loss in the same period last year. For the first six months, the net loss totaled $5.4 million.
-
Going Concern Warning Reiterated
Management again expressed substantial doubt about the company's ability to continue as a going concern, citing only $4.2 million in cash as of June 30, 2026.
-
ATM Sales Continue Post-Quarter
After June 30, 2026, the company issued 386,668 shares under its ATM Sales Agreement, generating net proceeds of $354,000.
-
Authorized Shares Increased to 500M
On July 17, 2026, shareholders approved an increase in authorized common stock from 166,666,667 to 500,000,000 shares, enabling further dilution.
Analysis · ARTL · Life Sciences
A net loss of $2.4 million for Q2 2026 pushed Artelo Biosciences' six-month deficit to $5.4 million. The company again flagged substantial doubt about its ability to continue as a going concern, with cash of just $4.2 million as of June 30, 2026. After the quarter ended, 386,668 shares were sold under the ATM for net proceeds of $354,000, and shareholders approved a 3x increase in authorized shares to 500 million, paving the way for further dilution. The stock trades near its 52-week low at $0.74, underscoring severe financial distress.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1503 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTL was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.71 to $31.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.